EirGenix Inc.

6589

TW0006589005

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
83.1 ^TWD	+2.34%		+3.88%	-17.31%

22/03	EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
08/03	EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	CI

EirGenix Inc. Announces Executive Changes

January 10, 2023 at 12:45 pm IST

EirGenix Inc. announced that Chun-Fu Lu, Chairman, Foxconn Technology Co. Ltd., has replaced Jih-Luh Tang as Representative of Juristic Person as Director, effective January 10, 2023.

Latest news about EirGenix Inc.

EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	08/03	CI
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	23/11	CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	09/11	CI
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	18/23/18	MT
Novartis Cancer Drug Gets Marketing Recommendation from European Medicines Agency	18/23/18	DJ
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	18/23/18	MT
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	18/23/18	CI
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	03/23/03	CI
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
EirGenix Inc. announced a financing transaction	10/23/10	CI
EirGenix Inc. Announces Executive Changes	10/23/10	CI
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	28/22/28	CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Eirgenix, Inc., Submits the Biosimilar Drug Eirgasum of 150 Mg Powder for Concentratefor Solution for Infusion Presentation New Drug Application to the Taiwan Food and Drug Administration	30/22/30	CI
EirGenix Inc. Appoints Po-Chih Chen as Remuneration Committee	08/22/08	CI
EirGenix Inc. Announces Board Changes	07/22/07	CI
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
EirGenix Inc. Announces Production Line Expansion and Production Equipment at Zhubei Facility	11/22/11	CI
EirGenix Inc. Announces Management Changes	10/22/10	CI
EirGenix Inc. Announces Board Appointments	10/22/10	CI
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	14/22/14	CI

EirGenix Inc is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for EirGenix Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

83.1 TWD

Average target price

132.5 TWD

Spread / Average Target

+59.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
EIRGENIX INC.	-17.31%	77Cr
CSL LIMITED	-2.32%	9.26TCr
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	4.14TCr
BIOGEN INC.	-11.26%	3.35TCr
BIOMARIN PHARMACEUTICAL INC.	-19.33%	1.46TCr
INCYTE CORPORATION	-9.01%	1.28TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	1.16TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	1.13TCr
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	896.84Cr
INNOVENT BIOLOGICS, INC.	-6.32%	829.97Cr

Biopharmaceuticals

EirGenix Inc.

Equities

6589

TW0006589005

Pharmaceuticals

EirGenix Inc. Announces Executive Changes

Latest news about EirGenix Inc.

Chart EirGenix Inc.

Company Profile

Income Statement Evolution

Ratings for EirGenix Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals